Nanotechnology Now - Press Release: Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory

Home > Press > Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory

Abstract:
The Long Island Capital Alliance ("LICA"), the leading non-profit capital formation and business development organization serving regional companies, today announced the presenting companies and panelists for its Biotech Technology Transfer Capital Forum to be held on June 14, 2013. The capital forum is being held in collaboration with Cold Spring Harbor Laboratory ("CSHL") in an effort to facilitate the formation and acceleration of high-growth businesses on Long Island, based on technologies developed at CSHL.

Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory

Melville, NY | Posted on June 8th, 2013

CSHL scientists will present some of the exciting new technologies developed there to biotech investors, and investors will have an opportunity to meet and establish relationships with the CSHL officials and scientists. Each of the underlying technologies LICA selected for presentation at the event is believed to represent catalysts for significant growth which will be attractive to investors and other financial backers. CSHL is continuing to expand its outreach and partnerships toward building locally-based companies around its technologies using the "technology transfer" concept.

Technology transfer involves the use of inventions, processes, and knowledge developed by subject matter experts to create and enhance private sector businesses. Technology transfer involves a wide range of approaches to get technologies to market, including licensing to larger, more established companies, establishing equity transactions to provide technology to startup businesses, and entering into research and development agreements, including Small Business Innovation Research (SBIR) programs, to collaboratively advance the technology toward commercialization.

A panel of investors and technology transfer experts will describe the process of financing and building companies around technological discoveries.

Biotech Technology Transfer Capital Forum on June 14, 2013 - Participants

Panel of Investors

Greg Blake: Mr. Blake founded Brocair Partners in 2004 with a focus on providing advisory services to healthcare companies on a variety of merger and acquisition, financing, and strategic matters. Mr. Blake has an exceptional set of senior-level relationships in the healthcare industry, and has worked with clients that range from large publicly-traded healthcare companies to small family-owned businesses.

Larry Chaityn: Larry Chaityn is a Managing Director and Head of Global Healthcare Banking at Kaminski Partners, a global investment bank. He is responsible for overseeing the day-to-day operations of the bank including deal sourcing, deal review, due diligence investigation and client-facing operations. He has 14 years of health care/life sciences advisory experience, is an active member in the venture capital and angel investment communities and in the National Association of Health Services Executives.

Scott Livingston: Mr. Livingston is the President of Livingston Securities, an investment banking firm that specializes in the nanotechnology and biosciences industries. Mr. Livingston has hosted the annual "Livingston Nanotechnology Conference," Wall Street's largest annual nanotechnology investor conference, since 2005.

Steve Winick: Steve Winick is a principal of Topspin Partners, one of Long Island's leading venture capital firms. Steve previously served as CIO of Honeywell International's $2B security group. He had been with Honeywell (and the Ademco division of Pittway Corp., before its acquisition by Honeywell in 2000) for over 21 years as CTO of the security business, as well as founder and president of its wireless communications services business.

Presenting Companies and Technologies

A Novel Treatment for Diabetes, Obesity and Cancer: exploiting an oral dosage of a key regulator of insulin, leptin and HER2 oncogene function. (Professor Nicholas Tonks, FRS)

RapidCaP: the next generation platform to cure metastatic prostate cancer. (Professor Lloyd Trotman)

Velocin-N™: a new enzyme that enables faster, more sensitive and more selective detection of proteins (the miniature machines and structures of life) in mass spectrometers. (Dr. John Wilson)

Wilson Advanced Research: develops products with novel health, social and commercial benefit, spanning a wide range from consumer products to environmental clean-up, including a simple solution to eliminate the largest reservoir of bacteria -- including MURSA and E. coli 0157 -- from homes. (Dr. John Wilson)

LICA, in collaboration with CSHL, will host the Biotech Technology Transfer Capital Forum on June 14, 2013 from 8:00 a.m. to 10:30 a.m. at 68 South Service Road, Melville, NY. The capital forum provides an opportunity to meet CSHL scientists, industry executives, capital providers, entrepreneurs, and businesses seeking capital, as well as to hear a panel of industry experts discuss financing alternatives for biotech technology transfer-based businesses.

For more information about the event, please contact LICA today or register online.

####

About Long Island Capital Alliance
Since 1984, the Long Island Capital Alliance (www.licapital.org), formerly known as Long Island Venture Group, has been promoting business growth on Long Island. LICA seeks to create a productive and business-friendly environment that will afford area businesses access to the resources necessary to compete successfully in today's markets. LICA serves as a focal point for the exchange of ideas among new and existing business enterprises, successful entrepreneurs, investors, and service providers. Through quarterly capital forums and special meetings, LICA brings together members of the region's business community, and has been recognized as the place to turn to when small businesses need equity, debt, or other financing, or for investors to find an attractive investment opportunity.

LICA's mission is to encourage economic development on Long Island by facilitating capital formation for a broad range of companies in various industries, from early stage to mature middle market closely held and publicly-traded businesses. LICA accomplishes this primarily through education, networking, quarterly capital forums, periodic special educational meetings, and alliances with other regional organizations. LICA brings together members of the region's business community and serves as the finance arm for significant local business and organizations.

For more information on LICA and its next event, please contact LICA today or register online.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.

For more information, please click here

Contacts:
Jordan Darrow
Darrow Associates, Inc.
(631) 367-1866

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: